Premium
Ph‐negative isolated myeloid sarcoma with NPM1 gene mutation in adolescent with Ph‐positive chronic myeloid leukemia in remission after treatment with allogeneic bone marrow transplantation and imatinib mesylate
Author(s) -
SkalskaSadowska Jolanta,
JanuszkiewiczLewandowska Danuta,
Derwich Katarzyna,
Pieczonka Anna,
Samborska Magdalena,
Wachowiak Jacek
Publication year - 2015
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.25428
Subject(s) - medicine , myeloid leukemia , chronic myelogenous leukemia , imatinib , imatinib mesylate , myeloid sarcoma , philadelphia chromosome , leukemia , bone marrow , cancer research , npm1 , oncology , immunology , karyotype , gene , chromosomal translocation , chromosome , biology , genetics
Few patients in remission of Ph‐positive chronic myelogenous leukemia (CML) develop Ph‐negative MDS/AML, usually with clonal cytogenetic abnormalities. Isolated Ph‐negative myeloid sarcoma (MS) is presented here as a form of such disorder, different from Ph‐positive MS establishing CML relapse in blastic phase. We describe 11‐year‐old male who developed Ph‐negative isolated MS with NPM1 mutation, remaining in complete molecular remission of Ph‐positive chronic myeloid leukemia treated with allo‐HSCT in first chronic phase and with imatinib and donor lymphocyte infusion in molecular relapse. The possible mechanisms of the tumor formation are reviewed with stress on importance of comprehensive molecular/cytogenetic evaluations. Pediatr Blood Cancer 2015;62:1070–1071. © 2015 Wiley Periodicals, Inc.